Teva Pharma Receives Buy Rating from Analysts

Published By : 30 Sep 2015 | Published By : QYRESEARCH

Research analysts at Zacks have given a ‘Buy’ rating to Teva Pharma Industries Ltd. with a rank of 2, whereas market experts at Wall Street have rated the company with an average of 1.88. 11 Wall Street analysts have given ‘Strong Buy’ to this stock, while another two have rated it a ‘Buy’. 6 experts have advised to ‘Hold’ the stock as of now, whereas only one analyst has given a ‘Strong Sell’ to the company’s stock.

Analysts at 15 stock trading firm have set the short term price target for Teva Pharma at US$76.47, taking the mean estimate into consideration. However, the standard deviation reading has suggested a stock price fluctuation by US$10.79 from the estimated price target with the higher estimate of the price target has been put at US$86, whereas the lower one has been at US$51.

Goldman Sachs have reinstated its rating on Teva Pharma Industries Ltd. The international giant brokerage firm has given a price target of US$80/share to this stock, at present and rated it with a ‘Buy’ rating on its shares on August 10th, 2015.

Institutional Investors possess 55.40% of the overall shares the company has. In the previous 3 months’ period, -0.70% of the overall institutional ownership has been transferred in the shares of the company.

The pharma company’s shares have grew 5.860% in the previous 52 weeks. The stock recorded a 1 year high of US$72.31 on July 28th, 2015 and a 1 year low at US$47.36 was witnessed on October 15th, 2014. The 50-day moving average of this stock is US$64.9, while US$63.24 is reported at its 200 day moving average

Back To Top